Joseph Beaulieu - 16 Aug 2021 Form 4 Insider Report for Epizyme, Inc.

Role: Corporate Controller
Signature: /s/ John Weidenbruch, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 16 Aug 2021
Net transactions value: $0
Form type: 4
Filing time: 18 Aug 2021, 08:07:06 UTC
Next filing: 04 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EPZM	Common Stock, par value $0.0001	Award	$0	+14,833	+110%	$0.000000	28,264	16 Aug 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EPZM	Stock Option (Right to Buy)	Award	$0	+22,250		$0.000000	22,250	16 Aug 2021	Common Stock	22,250	$5.31	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 14,833 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in two equal annual installments over two years from the grant date, with the first installment vesting on August 16, 2022.
F2	This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 22,250 shares of Common Stock, with 50% vesting on August 16, 2022 and the remaining 50% vesting on August 16, 2023.